Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Feasibility and effectiveness in clinical practice of a multifactorial intervention for the reduction of cardiovascular risk in patients with type 2 diabetes: the 2-year interim analysis of the MIND.IT study: a cluster randomized trial.
Vaccaro O, Franzini L, Miccoli R, Cavalot F, Ardigò D, Boemi M, De Feo P, Reboldi G, Rivellese AA, Trovati M, Zavaroni I; MIND.IT Study Group. Vaccaro O, et al. Among authors: cavalot f. Diabetes Care. 2013 Sep;36(9):2566-72. doi: 10.2337/dc12-1781. Epub 2013 Jul 17. Diabetes Care. 2013. PMID: 23863908 Free PMC article. Clinical Trial.
Treatment intensification following glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes: The RESTORE-G real-world study.
Candido R, Nicolucci A, Larosa M, Rossi MC, Napoli R; RESTORE-G (Retrospective analysis on the therapeutic approaches after GLP-1 RA treatment in type 2 diabetes patients) Study Group. Candido R, et al. Nutr Metab Cardiovasc Dis. 2023 Nov;33(11):2294-2305. doi: 10.1016/j.numecd.2023.07.025. Epub 2023 Jul 22. Nutr Metab Cardiovasc Dis. 2023. PMID: 37679243 Free article.
Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study.
Candido R, Nicolucci A, Larosa M, Rossi MC, Napoli R; RESTORE-G (Retrospective analysis on the therapeutic approaches after GLP-1 RA treatment in type 2 diabetes patients) Study Group. Candido R, et al. Nutr Metab Cardiovasc Dis. 2024 Mar 23:S0939-4753(24)00125-X. doi: 10.1016/j.numecd.2024.03.023. Online ahead of print. Nutr Metab Cardiovasc Dis. 2024. PMID: 38693036 Free article.
Sex Differences in Diagnosis, Treatment, and Cardiovascular Outcomes in Homozygous Familial Hypercholesterolemia.
Mulder JWCM, Tromp TR, Al-Khnifsawi M, Blom DJ, Chlebus K, Cuchel M, D'Erasmo L, Gallo A, Hovingh GK, Kim NT, Long J, Raal FJ, Schonck WAM, Soran H, Truong TH, Boersma E, Roeters van Lennep JE; Homozygous Familial Hypercholesterolemia International Clinical Collaborators. Mulder JWCM, et al. JAMA Cardiol. 2024 Apr 1;9(4):313-322. doi: 10.1001/jamacardio.2023.5597. JAMA Cardiol. 2024. PMID: 38353972
Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk.
Fadini GP, Longato E, Morieri ML, Del Prato S, Avogaro A, Solini A; DARWIN-Renal Study Investigators. Fadini GP, et al. Lancet Reg Health Eur. 2024 Feb 1;38:100847. doi: 10.1016/j.lanepe.2024.100847. eCollection 2024 Mar. Lancet Reg Health Eur. 2024. PMID: 38328413 Free PMC article.
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators. Agarwal R, et al. Ann Intern Med. 2023 Dec;176(12):1606-1616. doi: 10.7326/M23-1023. Epub 2023 Dec 5. Ann Intern Med. 2023. PMID: 38048573 Clinical Trial.
Sex Differences in Cardiovascular Disease and Cardiovascular Risk Estimation in Patients With Type 1 Diabetes.
Dei Cas A, Aldigeri R, Mantovani A, Masulli M, Palmisano L, Cavalot F, Bonomo K, Baroni MG, Cossu E, Cavallo G, Cimini FA, Buzzetti R, Mignogna C, Leonetti F, Bacci S, Trevisan R, Morieri ML, Pollis RM, Targher G, Vigili de Kreutzenberg S. Dei Cas A, et al. Among authors: cavalot f. J Clin Endocrinol Metab. 2023 Aug 18;108(9):e789-e798. doi: 10.1210/clinem/dgad127. J Clin Endocrinol Metab. 2023. PMID: 36881927
Body mass index versus surrogate measures of central adiposity as independent predictors of mortality in type 2 diabetes.
Orsi E, Solini A, Penno G, Bonora E, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Lamacchia O, Haxhi J, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Orsi E, et al. Among authors: cavalot f. Cardiovasc Diabetol. 2022 Dec 2;21(1):266. doi: 10.1186/s12933-022-01706-2. Cardiovasc Diabetol. 2022. PMID: 36461034 Free PMC article.
144 results